-
Je něco špatně v tomto záznamu ?
Cell death induced by taxanes in breast cancer cells: cytochrome C is released in resistant but not in sensitive cells
Ehrlichová M, Koc M, Truksa J, Naldová Z, Václavíková R, Kovárr J.
Jazyk angličtina Země Řecko
Grantová podpora
NL7567
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
NLK
Free Medical Journals
od 2004 do Před 2 roky
Open Access Digital Library
od 2004-01-01
- MeSH
- buněčná smrt fyziologie účinky léků MeSH
- buňky - růstové procesy účinky léků MeSH
- chemorezistence MeSH
- cytochromy c sekrece MeSH
- financování organizované MeSH
- fragmentace DNA účinky léků MeSH
- fytogenní protinádorové látky farmakologie MeSH
- inhibitor p21 cyklin-dependentní kinasy biosyntéza MeSH
- kaspasa 3 MeSH
- kaspasa 9 MeSH
- kaspasy metabolismus MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- nádorový supresorový protein p53 biosyntéza MeSH
- nádory prsu MeSH
- paclitaxel farmakologie MeSH
- taxoidy farmakologie MeSH
- Check Tag
- lidé MeSH
BACKGROUND: The aim of the study was to contribute to our understanding of the mechanisms responsible for the resistance of breast cancer cells to taxanes. MATERIALS AND METHODS: Cell cycle characteristics, DNA fragmentation, p53 and p21(WAF1/CIP1) expression, caspase-3 and caspase-9 activity, cytochrome c release from mitochondria during cell death induction by the taxanes paclitaxel and docetaxel in highly-sensitive MDA-MB-435 and highly-resistant NCI-ADR-RES human breast cancer cells were compared. RESULTS: Approximately 300-fold higher concentrations of the taxanes were required to induce death in resistant NCI-ADR-RES cells than in sensitive MDA-MB-435 cells. Cell death induced by the taxanes in both sensitive and resistant cells was preceded by the accumulation of cells in the G2/M-phase. Neither cell type produced any DNA fragmentation (DNA ladder) typical of regular apoptosis. The p53 and the p21(WAF1/CIP1) levels did not change in sensitive or in resistant cells during cell death induction by the taxanes. The activity of the executioner caspase-3 increased significantly (2 to 2.5-fold) and, similarly, the activity of caspase-9 increased significantly (2 to 3.5-fold) in both cell types. However, cytochrome c was found to be released from mitochondria into the cytosol only in the resistant NCI-ADR-RES cells, but not in the sensitive MDA-MB-435 cells. CONCLUSION: The death induced by the taxanes in the studied breast cancer cells can be characterized as an apoptosis-like death, including caspase-3 and caspase-9 activation but not oligonucleosomal DNA fragmentation. However, the mechanisms of death induction by the taxanes in sensitive MDA-MB-435 cells and resistant NCI-ADR-RES cells differ. Cytochrome c is released from the mitochondria in resistant but not in sensitive cells.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07520641
- 003
- CZ-PrNML
- 005
- 20130530113128.0
- 008
- 090405s2005 gr e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Ehrlichová, Marie $7 xx0067467
- 245 10
- $a Cell death induced by taxanes in breast cancer cells: cytochrome C is released in resistant but not in sensitive cells / $c Ehrlichová M, Koc M, Truksa J, Naldová Z, Václavíková R, Kovárr J.
- 314 __
- $a Cell Growth Control Laboratory, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague, Czech Republic
- 520 9_
- $a BACKGROUND: The aim of the study was to contribute to our understanding of the mechanisms responsible for the resistance of breast cancer cells to taxanes. MATERIALS AND METHODS: Cell cycle characteristics, DNA fragmentation, p53 and p21(WAF1/CIP1) expression, caspase-3 and caspase-9 activity, cytochrome c release from mitochondria during cell death induction by the taxanes paclitaxel and docetaxel in highly-sensitive MDA-MB-435 and highly-resistant NCI-ADR-RES human breast cancer cells were compared. RESULTS: Approximately 300-fold higher concentrations of the taxanes were required to induce death in resistant NCI-ADR-RES cells than in sensitive MDA-MB-435 cells. Cell death induced by the taxanes in both sensitive and resistant cells was preceded by the accumulation of cells in the G2/M-phase. Neither cell type produced any DNA fragmentation (DNA ladder) typical of regular apoptosis. The p53 and the p21(WAF1/CIP1) levels did not change in sensitive or in resistant cells during cell death induction by the taxanes. The activity of the executioner caspase-3 increased significantly (2 to 2.5-fold) and, similarly, the activity of caspase-9 increased significantly (2 to 3.5-fold) in both cell types. However, cytochrome c was found to be released from mitochondria into the cytosol only in the resistant NCI-ADR-RES cells, but not in the sensitive MDA-MB-435 cells. CONCLUSION: The death induced by the taxanes in the studied breast cancer cells can be characterized as an apoptosis-like death, including caspase-3 and caspase-9 activation but not oligonucleosomal DNA fragmentation. However, the mechanisms of death induction by the taxanes in sensitive MDA-MB-435 cells and resistant NCI-ADR-RES cells differ. Cytochrome c is released from the mitochondria in resistant but not in sensitive cells.
- 650 _2
- $a fytogenní protinádorové látky $x farmakologie $7 D000972
- 650 _2
- $a nádory prsu $7 D001943
- 650 _2
- $a buněčná smrt $x fyziologie $x účinky léků $7 D016923
- 650 _2
- $a kaspasy $x metabolismus $7 D020169
- 650 _2
- $a kaspasa 3 $7 D053148
- 650 _2
- $a kaspasa 9 $7 D053453
- 650 _2
- $a buňky - růstové procesy $x účinky léků $7 D048708
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a inhibitor p21 cyklin-dependentní kinasy $x biosyntéza $7 D050759
- 650 _2
- $a cytochromy c $x sekrece $7 D045304
- 650 _2
- $a fragmentace DNA $x účinky léků $7 D053938
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a paclitaxel $x farmakologie $7 D017239
- 650 _2
- $a taxoidy $x farmakologie $7 D043823
- 650 _2
- $a nádorový supresorový protein p53 $x biosyntéza $7 D016159
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Koc, Michal $7 xx0128600
- 700 1_
- $a Truksa, Jaroslav $7 xx0128857
- 700 1_
- $a Naldová, Zuzana $7 xx0128788
- 700 1_
- $a Václavíková, Radka $7 xx0142918
- 700 1_
- $a Kovář, Jan, $d 1952- $7 jn20040114001
- 773 0_
- $w MED00000478 $t Anticancer research $g Roč. 25, č. 6B (2005), s. 4215-4224 $x 0250-7005
- 910 __
- $a ABA008 $b x $y 9
- 990 __
- $a 20090310084605 $b ABA008
- 991 __
- $a 20130530113458 $b ABA008
- 999 __
- $a ok $b bmc $g 638445 $s 491257
- BAS __
- $a 3
- BMC __
- $a 2005 $b 25 $c 6B $d 4215-4224 $i 0250-7005 $m Anticancer research $x MED00000478
- GRA __
- $a NL7567 $p MZ0
- LZP __
- $a 2009-B1/jtme